Acetogenic Bacteria Cofactor Patents: Who Leads, Where Gaps Are 2026
Acetogenic bacteria cofactor engineering patents: who holds the redox balance claims
Concentrated at the top. Five assignees hold 70.3% of all 111 records in scope, and ten hold 83.8% — a short list controls most of the filed claim space. Filings rose unevenly through the period and peaked at 12 records in 2020. Because publication lags filing by roughly 18 months, the last one to two years in the chart understate real filing activity and should not be read as a slowdown.
- 1GENOMATICA INC37
- 2EVONIK OPERATIONS GMBH17
- 3YEDA RES & DEV CO LTD9
- 4MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV8
- 5JOHANN WOLFGANG GOETHE UNIV FRANKFURT AM MAIN7
See the full acetogenic bacteria cofactor engineering analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents on acetogenic bacteria cofactor engineering?
One assignee leads with 37 of the 111 records in scope, well ahead of the fifth-ranked assignee at 7. The top five assignees together account for 70.3% of all records, and the top ten for 83.8%, so the field is concentrated at the top with a long tail of smaller filers behind them. Anyone doing freedom-to-operate work should start with the leading assignee’s specific claim scope rather than searching the field broadly.
What technical areas does this patent search actually cover?
The search combines acetogenic bacteria or microorganism terms with redox and cofactor language — NADH balance, NADPH supply, redox ratio, cofactor recycling, electron transfer, or energy charge — restricted to microorganism, fermentation-product and enzyme-assay patent classes. It excludes general acetogen biology that does not touch redox or cofactor control directly, and it excludes filings outside those three IPC classes even if they mention acetogens.
Is patent filing in this area growing or slowing down?
The data does not support a clean growth or decline reading. Filing peaked at 12 records in 2020 rather than climbing steadily, and because patent publication typically lags filing by about 18 months, the most recent one to two years in the trend are understated and should not be read as a slowdown. A growth rate is not computable from this dataset once that lag is accounted for.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Acetogenic Bacteria Cofactor Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.